• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can GnRH Agonist be Combined with Ultrasound to Treat Adenomyosis?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Classic treatment for adenomyosis is hysterectomy but not necessarily appropriate for younger women
  • GnRH agonist therapy (GnRH-a) and high-intensity focused ultrasound (HIFU) have both been used independently but both approaches can be associated with recurrence of lack of pain relief
  • Guo et al. (BJOG, 2017) investigated the clinical efficacy of GnRH-a combined with HIFU ablation treatment for adenomyosis

METHODS:

  • A non-randomized prospective study (2014-2016)
  • Inclusion: Patients with adenomyosis
  • Patients were assigned to either:
    • Control group: Treated with only HIFU
    • Study group: Pretreatment with three courses of GnRH-a followed with HIFU ablation on day 28 after the third injection of GnRH-a
  • Primary outcomes
    • Serum levels of tumor markers and cytokines; MRI derived uterine and adenomyotic lesion volumes; menstrual blood loss and dysmenorrhea scores

RESULTS:

  • There were no differences between groups prior to treatment
  • The serum CA125 levels were significantly decreased in both groups after HIFU, but the serum CA125 levels in the study group were still significantly lower than among controls (p < 0.05)
  • The volume of uterine and adenomyotic lesions decreased in both groups, but was more marked in the study group 3 and 6 months after treatment (p < 0.05)
  • Dysmenorrhea scores and menstruation volumes were significantly decreased in both groups, but were significantly lower in the study group compared to the control group after 3 and 6 months (p< 0.05)
  • There was no significant difference in adverse events between groups

CONCLUSION:

  • In the HIFU pretreated with GnRH-a, at 6-month follow-up
    • Uterine volume was reduced by 21% and the adenomyotic lesion volume by 35%
    • Tumor markers/cytokines and symptoms such as dysmenorrhea were also significantly reduced
  • A larger, multi-center RCT is warranted to confirm findings

Learn More – Primary Sources:

Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

practical sexual health info for your healthcare practice
Your Patient Complains of Deep Pain with Intercourse – A Solution-based Approach
Does the Oral GnRH Antagonist Elagolix Improve Endometriosis-Associated Pain?
Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site